ICER publishes final evidence report on fezolinetant for vasomotor symptoms associated with menopause

23 January 2023 - Independent appraisal committee voted that evidence is not yet adequate to demonstrate a net health benefit ...

Read more →

ICER publishes second annual assessment of barriers to fair access within US commercial insurance prescription drug coverage

17 January 2023 - During ICER’s assessment, five payers revised policies for 11 medicines in ways that bring coverage into ...

Read more →

ICER releases draft evidence report on treatments for Alzheimer’s disease

22 December 2022 - Registration now open for 5 January “Early Insights” webinar. ...

Read more →

ICER publishes final evidence report on gene therapies for haemophilia A and B

22 December 2022 - Fair pricing benchmarks suggest upper bounds for price of Roctavian at approximately $1.9 million and for Hemgenix ...

Read more →

ICER publishes evidence report on treatments for multiple sclerosis

21 December 2022 - Evidence is rated as insufficient to differentiate the net health benefit between ublituximab and other monoclonal antibodies; ...

Read more →

ICER provides update on value based pricing of Paxlovid as an outpatient treatment for COVID-19

20 December 2022 - New data suggests Paxlovid will achieve common thresholds of cost effectiveness if priced between $563-$906 per treatment ...

Read more →

ICER publishes evidence report on fezolinetant for vasomotor symptoms associated with menopause

1 December 2022 - Evidence is rated as promising but inconclusive to determine whether fezolinetant provides a net health benefit for ...

Read more →

ICER to assess gene therapies for sickle cell disease

23 November 2022 - Report will be subject of CTAF meeting in June 2023; draft scoping document open to public ...

Read more →

ICER publishes evidence report on gene therapies for haemophilia A and B

2 November 2022 - Duration of benefit with gene therapies and risks for rare side effects remain major uncertainties. ...

Read more →

Patient centred health technology assessment: a perspective on engagement in health technology assessment by three patient organisations and a health technology assessment body

20 October 2022 - Patient engagement in health technology assessment has become increasingly important over the past 20 years.  ...

Read more →

ICER publishes final evidence report and policy recommendations on treatments for obesity management

20 October 2022 - Independent appraisal committee voted that evidence is adequate to demonstrate that semaglutide provides a net health benefit ...

Read more →

ICER evaluates drug price increases in California

20 October 2022 - Unsupported Price Increase” final report based on drugs identified through SB-17, the California drug price transparency law. ...

Read more →

Can state prescription drug affordability boards address high cost drug prices?

11 October 2022 - State law makers, like their federal counterparts, are focused on addressing the high and growing cost of ...

Read more →

ICER releases draft evidence report on treatments for multiple sclerosis

17 October 2022 - Public comment period now open until 11 November 2022; requests to make oral comment during public ...

Read more →

HARmonized protocol template to enhance reproducibility of hypothesis evaluating real world evidence studies on treatment effects: a good practices report of a joint ISPE/ISPOR Task Force

12 October 2022 - Ambiguity in communication of key study parameters limits the utility of real-world evidence studies in health care ...

Read more →